Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

23 matching registry records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 17:42 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 1 / Phase 2CompletedINTERVENTIONAL

Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients

ClinicalTrials.gov · NCT06388642 · Registry updated: 2026-07-27

Condition / research focus: Erythropoietic Protoporphyria
Sponsor: Clinuvel Europe Limited
Countries with listed sites: Belgium · Netherlands
Registry dates and results: Start: 2024-03-07. Completion: 2025-01-20 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide 16mg implant (drug) — also listed as: SCENESSE®

Where the study takes place — 2 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

CLINUVEL Site
Leuven, Belgium
Site recruitment: Not reported
CLINUVEL Site
Rotterdam, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Active, not recruitingINTERVENTIONAL

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

ClinicalTrials.gov · NCT06109649 · Registry updated: 2025-07-08

Condition / research focus: Vitiligo
Sponsor: Clinuvel, Inc.
Countries with listed sites: France · Kenya · United Kingdom · United States
Registry dates and results: Start: 2023-10-11. Completion: 2026-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide and NB-UVB Light (drug)
NB-UVB Light (procedure)

Where the study takes place — 30 listed sites

CLINUVEL site
Birmingham, Alabama, United States
Site recruitment: Not reported
CLINUVEL site
Fresno, California, United States
Site recruitment: Not reported
CLINUVEL site
Los Angeles, California, United States
Site recruitment: Not reported
CLINUVEL site
Palo Alto, California, United States
Site recruitment: Not reported
CLINUVEL site
San Diego, California, United States
Site recruitment: Not reported
CLINUVEL Site
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
CLINUVEL site
Miami, Florida, United States
Site recruitment: Not reported
CLINUVEL site
Miramar, Florida, United States
Site recruitment: Not reported
CLINUVEL site
Alpharetta, Georgia, United States
Site recruitment: Not reported
CLINUVEL site
Augusta, Georgia, United States
Site recruitment: Not reported
CLINUVEL site
Chicago, Illinois, United States
Site recruitment: Not reported
CLINUVEL site
Baton Rouge, Louisiana, United States
Site recruitment: Not reported
CLINUVEL site
Detroit, Michigan, United States
Site recruitment: Not reported
CLINUVEL site
Minneapolis, Minnesota, United States
Site recruitment: Not reported
CLINUVEL site
Roseville, Minnesota, United States
Site recruitment: Not reported
CLINUVEL Site
Lee's Summit, Missouri, United States
Site recruitment: Not reported
CLINUVEL site
Rochester, New York, United States
Site recruitment: Not reported
CLINUVEL site
Cleveland, Ohio, United States
Site recruitment: Not reported
CLINUVEL site
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
CLINUVEL Site
Charleston, South Carolina, United States
Site recruitment: Not reported
CLINUVEL site
Thompson's Station, Tennessee, United States
Site recruitment: Not reported
CLINUVEL Site
Cedar Park, Texas, United States
Site recruitment: Not reported
CLINUVEL site
Dallas, Texas, United States
Site recruitment: Not reported
CLINUVEL site
Tyler, Texas, United States
Site recruitment: Not reported
CLINUVEL site
Charlottesville, Virginia, United States
Site recruitment: Not reported
CLINUVEL site
La Réunion, France
Site recruitment: Not reported
CLINUVEL site
Nice, France
Site recruitment: Not reported
CLINUVEL site
Nairobi, Kenya
Site recruitment: Not reported
CLINUVEL site
London, United Kingdom
Site recruitment: Not reported
CLINUVEL site
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)

ClinicalTrials.gov · NCT05854784 · Registry updated: 2025-04-27

Condition / research focus: Variegate Porphyria
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: Netherlands
Registry dates and results: Start: 2023-03-28. Completion: 2023-12-28 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide 16 MG (drug)

Where the study takes place — 1 listed sites

CLINUVEL investigational site
Rotterdam, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)

ClinicalTrials.gov · NCT04525157 · Registry updated: 2023-09-22

Condition / research focus: Vitiligo
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2014-06-06. Completion: 2016-06-06 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V

ClinicalTrials.gov · NCT05370235 · Registry updated: 2023-09-21

Condition / research focus: Xeroderma Pigmentosum
Sponsor: Clinuvel Europe Limited
Countries with listed sites: Belgium · Spain
Registry dates and results: Start: 2022-03-28. Completion: 2024-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)

Where the study takes place — 2 listed sites

CLINUVEL Investigational site
Clinuvel Investigational Site, Belgium
Site recruitment: Recruiting
CLINUVEL Investigational site
Clinuvel Investigational Site, Spain
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)

ClinicalTrials.gov · NCT05159752 · Registry updated: 2023-06-18

Condition / research focus: Xeroderma Pigmentosum
Sponsor: Clinuvel Europe Limited
Countries with listed sites: Germany
Registry dates and results: Start: 2021-10-19. Completion: 2024-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)

Where the study takes place — 1 listed sites

CLINUVEL investigative site
Regensburg, Germany
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)

ClinicalTrials.gov · NCT04962503 · Registry updated: 2023-04-11

Condition / research focus: Arterial Ischemic Stroke
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: Australia
Registry dates and results: Start: 2021-06-03. Completion: 2022-02-04 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)

Where the study takes place — 1 listed sites

The Alfred
Melbourne, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face

ClinicalTrials.gov · NCT05210582 · Registry updated: 2023-02-09

Condition / research focus: Vitiligo
Sponsor: Clinuvel, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2022-10-11. Completion: 2023-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)

Where the study takes place — 1 listed sites

CLINUVEL Investigational site
Detroit, Michigan, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy Volunteers

ClinicalTrials.gov · NCT05368857 · Registry updated: 2023-02-09

Condition / research focus: Afamelanotide Evaluated as Skin DNA Repair Therapy in Healthy Volunteers
Sponsor: Clinuvel (UK) Ltd.
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2022-01-19. Completion: 2023-02-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)

Where the study takes place — 1 listed sites

CLINUVEL Investigational Site
Clinuvel Investigational Site, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Afamelanotide in Patients Suffering With Acne Vulgaris

ClinicalTrials.gov · NCT04943159 · Registry updated: 2021-10-26

Condition / research focus: Acne Vulgaris
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2010-08-24. Completion: 2011-03-08 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)

ClinicalTrials.gov · NCT00979745 · Registry updated: 2021-10-12

Condition / research focus: Erythropoietic Protoporphyria
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: Finland · France · Germany · Ireland · Netherlands · United Kingdom
Registry dates and results: Start: 2009-09. Completion: 2011-05 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug) — also listed as: CUV1647
Placebo (drug)

Where the study takes place — 8 listed sites

HUS:n Iho-ja allergiasairaala (Skin and Allergy Hospital)
Helsinki, Finland
Site recruitment: Not reported
Centre Français des Porphyries, Hôpital Louis Mourier
Colombes, Cedex, France
Site recruitment: Not reported
Department of Dermatology , Heinrich-Heine-University Duesseldorf
Düsseldorf, Germany
Site recruitment: Not reported
Beaumont Hospital, Department of Dermatology
Dublin, Ireland
Site recruitment: Not reported
Academisch Ziekenhuis Maastricht
Maastricht, Netherlands
Site recruitment: Not reported
Erasmus Medical Center
Rotterdam, Netherlands
Site recruitment: Not reported
St Woolos Hospital
Newport, Wales, United Kingdom
Site recruitment: Not reported
Photobiology Unit - Hope Hospital, University of Manchester
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium

ClinicalTrials.gov · NCT04425746 · Registry updated: 2021-10-01

Condition / research focus: Patients Undergoing Photodynamic Therapy Using Porfimer Sodium
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2008-08-05. Completion: 2009-05-28 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)

ClinicalTrials.gov · NCT04704713 · Registry updated: 2021-03-19

Condition / research focus: Polymorphic Light Eruption
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2010-05-05. Completion: Not reported (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)

ClinicalTrials.gov · NCT04578496 · Registry updated: 2020-11-19

Condition / research focus: Erythropoietic Protoporphyria
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2011-07-11. Completion: 2014-02-27 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)

ClinicalTrials.gov · NCT01097044 · Registry updated: 2019-10-28

Condition / research focus: Erythropoietic Protoporphyria
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: United States
Registry dates and results: Start: 2010-04. Completion: 2011-04 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)
Placebo (drug)

Where the study takes place — 6 listed sites

University of Alabama
Birmingham, Alabama, United States
Site recruitment: Not reported
University of California, San Francisco
San Francisco, California, United States
Site recruitment: Not reported
Mt. Sinai
New York, New York, United States
Site recruitment: Not reported
Carolina's Medical Center Cannon Research
Charlotte, North Carolina, United States
Site recruitment: Not reported
University of Texas
Galveston, Texas, United States
Site recruitment: Not reported
University of Utah
Salt Lake City, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Multicentre Phase III Erythropoietic Protoporphyria Study

ClinicalTrials.gov · NCT04053270 · Registry updated: 2019-10-10

Condition / research focus: Erythropoietic Protoporphyria
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2007-05. Completion: 2009-12-09 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Phase III Confirmatory Study in Erythropoietic Protoporphyria

ClinicalTrials.gov · NCT01605136 · Registry updated: 2019-09-19

Condition / research focus: Erythropoietic Protoporphyria
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: United States
Registry dates and results: Start: 2012-05. Completion: 2013-07 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)
Placebo (drug)

Where the study takes place — 7 listed sites

University of Alabama
Birmingham, Alabama, United States
Site recruitment: Not reported
University of California, San Francisco
San Francisco, California, United States
Site recruitment: Not reported
Henry Ford Medical Center
Detroit, Michigan, United States
Site recruitment: Not reported
Mt. Sinai
New York, New York, United States
Site recruitment: Not reported
Carolina's Medical Center Cannon Research
Charlotte, North Carolina, United States
Site recruitment: Not reported
University of Texas
Galveston, Texas, United States
Site recruitment: Not reported
University of Utah
Salt Lake City, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Implant Pharmacokinetic and Pharmacodynamic Study

ClinicalTrials.gov · NCT03634137 · Registry updated: 2018-08-16

Condition / research focus: Healthy
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: United States
Registry dates and results: Start: 2009-09. Completion: 2010-03 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide Group 1 (drug) — also listed as: afamelanotide
Afamelanotide Group 2 (drug) — also listed as: afamelanotide

Where the study takes place — 1 listed sites

Prism Research Inc.
Saint Paul, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo

ClinicalTrials.gov · NCT01382589 · Registry updated: 2013-03-22

Condition / research focus: Vitiligo
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2011-09. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug) — also listed as: CUV1647
NB-UVB (device)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)

ClinicalTrials.gov · NCT01430195 · Registry updated: 2013-03-22

Condition / research focus: Vitiligo
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: United States
Registry dates and results: Start: 2011-06. Completion: 2012-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug) — also listed as: CUV1647
Narrow-Band UVB Light Treatment (procedure) — also listed as: NB-UVB light treatment

Where the study takes place — 2 listed sites

Henry Ford Medical Center
Detroit, Michigan, United States
Site recruitment: Not reported
The Mount Sinai School of Medicine
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

23 matching registry records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 17:42 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 1 / Phase 2CompletedINTERVENTIONAL

Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients

ClinicalTrials.gov · NCT06388642 · Registry updated: 2026-07-27

Condition / research focus: Erythropoietic Protoporphyria
Sponsor: Clinuvel Europe Limited
Countries with listed sites: Belgium · Netherlands
Registry dates and results: Start: 2024-03-07. Completion: 2025-01-20 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide 16mg implant (drug) — also listed as: SCENESSE®

Where the study takes place — 2 listed sites

CLINUVEL Site
Leuven, Belgium
Site recruitment: Not reported
CLINUVEL Site
Rotterdam, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Active, not recruitingINTERVENTIONAL

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

ClinicalTrials.gov · NCT06109649 · Registry updated: 2025-07-08

Condition / research focus: Vitiligo
Sponsor: Clinuvel, Inc.
Countries with listed sites: France · Kenya · United Kingdom · United States
Registry dates and results: Start: 2023-10-11. Completion: 2026-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide and NB-UVB Light (drug)
NB-UVB Light (procedure)

Where the study takes place — 30 listed sites

CLINUVEL site
Birmingham, Alabama, United States
Site recruitment: Not reported
CLINUVEL site
Fresno, California, United States
Site recruitment: Not reported
CLINUVEL site
Los Angeles, California, United States
Site recruitment: Not reported
CLINUVEL site
Palo Alto, California, United States
Site recruitment: Not reported
CLINUVEL site
San Diego, California, United States
Site recruitment: Not reported
CLINUVEL Site
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
CLINUVEL site
Miami, Florida, United States
Site recruitment: Not reported
CLINUVEL site
Miramar, Florida, United States
Site recruitment: Not reported
CLINUVEL site
Alpharetta, Georgia, United States
Site recruitment: Not reported
CLINUVEL site
Augusta, Georgia, United States
Site recruitment: Not reported
CLINUVEL site
Chicago, Illinois, United States
Site recruitment: Not reported
CLINUVEL site
Baton Rouge, Louisiana, United States
Site recruitment: Not reported
CLINUVEL site
Detroit, Michigan, United States
Site recruitment: Not reported
CLINUVEL site
Minneapolis, Minnesota, United States
Site recruitment: Not reported
CLINUVEL site
Roseville, Minnesota, United States
Site recruitment: Not reported
CLINUVEL Site
Lee's Summit, Missouri, United States
Site recruitment: Not reported
CLINUVEL site
Rochester, New York, United States
Site recruitment: Not reported
CLINUVEL site
Cleveland, Ohio, United States
Site recruitment: Not reported
CLINUVEL site
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
CLINUVEL Site
Charleston, South Carolina, United States
Site recruitment: Not reported
CLINUVEL site
Thompson's Station, Tennessee, United States
Site recruitment: Not reported
CLINUVEL Site
Cedar Park, Texas, United States
Site recruitment: Not reported
CLINUVEL site
Dallas, Texas, United States
Site recruitment: Not reported
CLINUVEL site
Tyler, Texas, United States
Site recruitment: Not reported
CLINUVEL site
Charlottesville, Virginia, United States
Site recruitment: Not reported
CLINUVEL site
La Réunion, France
Site recruitment: Not reported
CLINUVEL site
Nice, France
Site recruitment: Not reported
CLINUVEL site
Nairobi, Kenya
Site recruitment: Not reported
CLINUVEL site
London, United Kingdom
Site recruitment: Not reported
CLINUVEL site
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)

ClinicalTrials.gov · NCT05854784 · Registry updated: 2025-04-27

Condition / research focus: Variegate Porphyria
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: Netherlands
Registry dates and results: Start: 2023-03-28. Completion: 2023-12-28 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide 16 MG (drug)

Where the study takes place — 1 listed sites

CLINUVEL investigational site
Rotterdam, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)

ClinicalTrials.gov · NCT04525157 · Registry updated: 2023-09-22

Condition / research focus: Vitiligo
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2014-06-06. Completion: 2016-06-06 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V

ClinicalTrials.gov · NCT05370235 · Registry updated: 2023-09-21

Condition / research focus: Xeroderma Pigmentosum
Sponsor: Clinuvel Europe Limited
Countries with listed sites: Belgium · Spain
Registry dates and results: Start: 2022-03-28. Completion: 2024-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)

Where the study takes place — 2 listed sites

CLINUVEL Investigational site
Clinuvel Investigational Site, Belgium
Site recruitment: Recruiting
CLINUVEL Investigational site
Clinuvel Investigational Site, Spain
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)

ClinicalTrials.gov · NCT05159752 · Registry updated: 2023-06-18

Condition / research focus: Xeroderma Pigmentosum
Sponsor: Clinuvel Europe Limited
Countries with listed sites: Germany
Registry dates and results: Start: 2021-10-19. Completion: 2024-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)

Where the study takes place — 1 listed sites

CLINUVEL investigative site
Regensburg, Germany
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)

ClinicalTrials.gov · NCT04962503 · Registry updated: 2023-04-11

Condition / research focus: Arterial Ischemic Stroke
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: Australia
Registry dates and results: Start: 2021-06-03. Completion: 2022-02-04 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)

Where the study takes place — 1 listed sites

The Alfred
Melbourne, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face

ClinicalTrials.gov · NCT05210582 · Registry updated: 2023-02-09

Condition / research focus: Vitiligo
Sponsor: Clinuvel, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2022-10-11. Completion: 2023-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)

Where the study takes place — 1 listed sites

CLINUVEL Investigational site
Detroit, Michigan, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy Volunteers

ClinicalTrials.gov · NCT05368857 · Registry updated: 2023-02-09

Condition / research focus: Afamelanotide Evaluated as Skin DNA Repair Therapy in Healthy Volunteers
Sponsor: Clinuvel (UK) Ltd.
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2022-01-19. Completion: 2023-02-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)

Where the study takes place — 1 listed sites

CLINUVEL Investigational Site
Clinuvel Investigational Site, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Afamelanotide in Patients Suffering With Acne Vulgaris

ClinicalTrials.gov · NCT04943159 · Registry updated: 2021-10-26

Condition / research focus: Acne Vulgaris
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2010-08-24. Completion: 2011-03-08 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)

ClinicalTrials.gov · NCT00979745 · Registry updated: 2021-10-12

Condition / research focus: Erythropoietic Protoporphyria
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: Finland · France · Germany · Ireland · Netherlands · United Kingdom
Registry dates and results: Start: 2009-09. Completion: 2011-05 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug) — also listed as: CUV1647
Placebo (drug)

Where the study takes place — 8 listed sites

HUS:n Iho-ja allergiasairaala (Skin and Allergy Hospital)
Helsinki, Finland
Site recruitment: Not reported
Centre Français des Porphyries, Hôpital Louis Mourier
Colombes, Cedex, France
Site recruitment: Not reported
Department of Dermatology , Heinrich-Heine-University Duesseldorf
Düsseldorf, Germany
Site recruitment: Not reported
Beaumont Hospital, Department of Dermatology
Dublin, Ireland
Site recruitment: Not reported
Academisch Ziekenhuis Maastricht
Maastricht, Netherlands
Site recruitment: Not reported
Erasmus Medical Center
Rotterdam, Netherlands
Site recruitment: Not reported
St Woolos Hospital
Newport, Wales, United Kingdom
Site recruitment: Not reported
Photobiology Unit - Hope Hospital, University of Manchester
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium

ClinicalTrials.gov · NCT04425746 · Registry updated: 2021-10-01

Condition / research focus: Patients Undergoing Photodynamic Therapy Using Porfimer Sodium
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2008-08-05. Completion: 2009-05-28 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)

ClinicalTrials.gov · NCT04704713 · Registry updated: 2021-03-19

Condition / research focus: Polymorphic Light Eruption
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2010-05-05. Completion: Not reported (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)

ClinicalTrials.gov · NCT04578496 · Registry updated: 2020-11-19

Condition / research focus: Erythropoietic Protoporphyria
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2011-07-11. Completion: 2014-02-27 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)

ClinicalTrials.gov · NCT01097044 · Registry updated: 2019-10-28

Condition / research focus: Erythropoietic Protoporphyria
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: United States
Registry dates and results: Start: 2010-04. Completion: 2011-04 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)
Placebo (drug)

Where the study takes place — 6 listed sites

University of Alabama
Birmingham, Alabama, United States
Site recruitment: Not reported
University of California, San Francisco
San Francisco, California, United States
Site recruitment: Not reported
Mt. Sinai
New York, New York, United States
Site recruitment: Not reported
Carolina's Medical Center Cannon Research
Charlotte, North Carolina, United States
Site recruitment: Not reported
University of Texas
Galveston, Texas, United States
Site recruitment: Not reported
University of Utah
Salt Lake City, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Multicentre Phase III Erythropoietic Protoporphyria Study

ClinicalTrials.gov · NCT04053270 · Registry updated: 2019-10-10

Condition / research focus: Erythropoietic Protoporphyria
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2007-05. Completion: 2009-12-09 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Phase III Confirmatory Study in Erythropoietic Protoporphyria

ClinicalTrials.gov · NCT01605136 · Registry updated: 2019-09-19

Condition / research focus: Erythropoietic Protoporphyria
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: United States
Registry dates and results: Start: 2012-05. Completion: 2013-07 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug)
Placebo (drug)

Where the study takes place — 7 listed sites

University of Alabama
Birmingham, Alabama, United States
Site recruitment: Not reported
University of California, San Francisco
San Francisco, California, United States
Site recruitment: Not reported
Henry Ford Medical Center
Detroit, Michigan, United States
Site recruitment: Not reported
Mt. Sinai
New York, New York, United States
Site recruitment: Not reported
Carolina's Medical Center Cannon Research
Charlotte, North Carolina, United States
Site recruitment: Not reported
University of Texas
Galveston, Texas, United States
Site recruitment: Not reported
University of Utah
Salt Lake City, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Implant Pharmacokinetic and Pharmacodynamic Study

ClinicalTrials.gov · NCT03634137 · Registry updated: 2018-08-16

Condition / research focus: Healthy
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: United States
Registry dates and results: Start: 2009-09. Completion: 2010-03 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide Group 1 (drug) — also listed as: afamelanotide
Afamelanotide Group 2 (drug) — also listed as: afamelanotide

Where the study takes place — 1 listed sites

Prism Research Inc.
Saint Paul, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo

ClinicalTrials.gov · NCT01382589 · Registry updated: 2013-03-22

Condition / research focus: Vitiligo
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: No country reported
Registry dates and results: Start: 2011-09. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug) — also listed as: CUV1647
NB-UVB (device)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)

ClinicalTrials.gov · NCT01430195 · Registry updated: 2013-03-22

Condition / research focus: Vitiligo
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: United States
Registry dates and results: Start: 2011-06. Completion: 2012-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (drug) — also listed as: CUV1647
Narrow-Band UVB Light Treatment (procedure) — also listed as: NB-UVB light treatment

Where the study takes place — 2 listed sites

Henry Ford Medical Center
Detroit, Michigan, United States
Site recruitment: Not reported
The Mount Sinai School of Medicine
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →